Robert Dee Etherington
Chief Executive Officer chez CLENE INC.
Fortune : 40 082 $ au 31/03/2024
Profil
Robert Dee Etherington is currently the President, Chief Executive Officer & Director at Clene Nanomedicine, Inc. and Clene, Inc. He is also a Director at BioUtah and Corsair LLC.
Previously, he worked as the Marketing Director at Actelion Pharmaceuticals Ltd.
from 2000 to 2013.
Mr. Etherington completed his undergraduate degree at Brigham Young University in 1990 and obtained an MBA in 1992.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
CLENE INC
0,07% | 01/04/2024 | 94 310 ( 0,07% ) | 40 082 $ | 31/03/2024 |
Postes actifs de Robert Dee Etherington
| Sociétés | Poste | Début |
|---|---|---|
| CLENE INC. | Chief Executive Officer | 01/04/2013 |
| BioUtah | Director/Board Member | 01/06/2016 |
Clene Nanomedicine, Inc.
 Clene Nanomedicine, Inc. Pharmaceuticals: MajorHealth Technology Clene Nanomedicine, Inc. is a clinical-stage biopharmaceutical company, which develops therapeutic candidates for neurodegenerative diseases. It focuses on the development of therapeutic nanocatalyst, CNM-Au8, for treatment of neurodegenerative diseases with a Phase 3 study underway in amyotrophic lateral sclerosis (ALS), and concurrent Phase 2 clinical programs ongoing for the neuroreparative treatment of multiple sclerosis, Parkinson's disease, and ALS. The company was founded by Reed N. Wilcox and Mark G. Mortenson in 2013 and and is headquartered in Salt Lake City, UT. | Chief Executive Officer | 01/04/2013 |
| Corsair LLC | Director/Board Member | 01/03/2018 |
Anciens postes connus de Robert Dee Etherington
| Sociétés | Poste | Fin |
|---|---|---|
Actelion Pharmaceuticals Ltd.
 Actelion Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Part of Johnson & Johnson, Actelion Pharmaceuticals Ltd. is a Swiss company that develops and distributes molecular weight drugs. The private company is based in Allschwil, Switzerland. | Sales & Marketing | 01/03/2013 |
Formation de Robert Dee Etherington
| Brigham Young University | Masters Business Admin |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| CLENE INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
| BioUtah | |
Clene Nanomedicine, Inc.
Clene Nanomedicine, Inc. Pharmaceuticals: MajorHealth Technology Clene Nanomedicine, Inc. is a clinical-stage biopharmaceutical company, which develops therapeutic candidates for neurodegenerative diseases. It focuses on the development of therapeutic nanocatalyst, CNM-Au8, for treatment of neurodegenerative diseases with a Phase 3 study underway in amyotrophic lateral sclerosis (ALS), and concurrent Phase 2 clinical programs ongoing for the neuroreparative treatment of multiple sclerosis, Parkinson's disease, and ALS. The company was founded by Reed N. Wilcox and Mark G. Mortenson in 2013 and and is headquartered in Salt Lake City, UT. | Health Technology |
Actelion Pharmaceuticals Ltd.
Actelion Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Part of Johnson & Johnson, Actelion Pharmaceuticals Ltd. is a Swiss company that develops and distributes molecular weight drugs. The private company is based in Allschwil, Switzerland. | Health Technology |
| Corsair LLC |
